Can Sydnexis’ SYD-101 data sharpen the case for low-dose atropine in fast-progressing pediatric myopia?
Pediatric myopia is rising fast, but U.S. drug options remain thin. Sydnexis’ SYD-101 data may sharpen the regulatory race.
Pediatric myopia is rising fast, but U.S. drug options remain thin. Sydnexis’ SYD-101 data may sharpen the regulatory race.